Shield the healthy cells, attack the cancer
We aim to cure blood cancers through cell and genome engineering
The Science
Our novel approach to shielding healthy cells aims to transform blood cancer treatment.
Vor Bio is developing a proprietary platform built on Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T Cells.
Our Approach
Shielded transplants potentially enable curative targeted therapy opportunities for blood cancers
We’re applying the latest scientific advancements to fight AML and other blood cancers in a new way.
The Vor Bio Platform
We are working to cure AML and then go further
Our proprietary platform combines genome engineering, Hematopoietic Stem Cell (HSC) biology, and CAR-T cells to solve urgent unmet medical needs for patients with blood cancers.
Understanding Our Impact
For Patients & Caregivers
Our Investigational Program
We aim to transform treatment by shielding the healthy blood cells and only attacking the cancer cells with targeted therapies post-transplant.
Our Clinical Trials
We are currently conducting several clinical trials to further investigate our promising approach to shield healthy cells.
Patient / Donor Journey
Our approach shields healthy cells enabling multiple modalities and therapies post-transplant, including ADCs and CAR-Ts, which by themselves are highly toxic.
The Science Behind Our Approach
For Medical Professionals
Our Investigational Program
By shielding healthy cells, we are aiming to delay or prevent relapse and enable cures for patients with AML and other blood cancers.
Clinical Trials
Our clinical trials are actively recruiting patients.
Join Our Team
Passion. Fellowship. Humility.
Come be a part of a team that is developing a unique approach to one of medicine’s greatest challenges—eradicating cancer.